Luvometinib in Combination With Serplulimab for NF2-Related Tumors

Summary

This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.

Timeline

Start

2026-07-31

Primary completion

2028-12-31

Completion

2029-12-31

Drugs

Indications